| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Signal Transduction and Molecular Pharmacology Team, Cancer Research UK Centre for Cancer Therapeutics, Haddow Laboratories, The Institute of Cancer Research, Sutton, Surrey SM2 5NG, UK
(Requests for offprints should be addressed to P Workman; Email: paul.workman{at}icr.ac.uk)
This paper was presented at the 2nd Tenovus/AstraZeneca Workshop, Cardiff (2006). AstraZeneca supported the meeting and the Welsh School of Pharmacy, Cardiff University has supported the publication of these proceedings.
The last decade has seen the molecular chaperone heat shock protein 90 (HSP90) emerge as an exciting target for cancer therapy. This is because HSP90 is involved in maintaining the conformation, stability, activity and cellular localisation of several key oncogenic client proteins. These include, amongst others, ERBB2, C-RAF, CDK4, AKT/PKB, steroid hormone receptors, mutant p53, HIF-1
, survivin and telomerase hTERT. Therefore, modulation of this single drug target offers the prospect of simultaneously inhibiting all the multiple signalling pathways and biological processes that have been implicated in the development of the malignant phenotype. The chaperone function of HSP90 requires the formation of a multichaperone complex, which is dependent on the hydrolysis of ATP and ADP/ATP exchange. Most current inhibitors of HSP90 act as nucleotide mimetics, which block the intrinsic ATPase activity of this molecular chaperone. The first-in-class inhibitor to enter and complete phase I clinical trials was the geldanamycin analogue, 17-allylamino-17-demethoxygeldanamycin. The results of these trials have demonstrated that HSP90 is a valid drug target. Evidence of clinical activity has been seen in patients with melanoma, breast and prostate cancer. This article provides a personal perspective of the present efforts to increase our understanding of the molecular and cellular consequences of HSP90 inhibition, with examples from work in our own laboratory. We also review the discovery and development of novel small-molecule inhibitors and discuss alternative approaches to inhibit HSP90 activity, both of which offer exciting prospects for the future.
This article has been cited by other articles:
|
|
 |
|
  C. Stuehler, S. Mielke, M. Chatterjee, J. Duell, S. Lurati, F. Rueckert, H. Einsele, R. C. Bargou, and M. S. Topp Selective depletion of alloreactive T cells by targeted therapy of heat shock protein 90: a novel strategy for control of graft-versus-host disease Blood, September 24, 2009; 114(13): 2829 - 2836. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Bao, C.-J. Lai, H. Qu, D. Wang, L. Yin, B. Zifcak, R. Atoyan, J. Wang, M. Samson, J. Forrester, et al. CUDC-305, a Novel Synthetic HSP90 Inhibitor with Unique Pharmacologic Properties for Cancer Therapy Clin. Cancer Res., June 15, 2009; 15(12): 4046 - 4057. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Cervantes-Gomez, R. Nimmanapalli, and V. Gandhi Transcription Inhibition of Heat Shock Proteins: A Strategy for Combination of 17-Allylamino-17-Demethoxygeldanamycin and Actinomycin D Cancer Res., May 1, 2009; 69(9): 3947 - 3954. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Ross, E. A. Slodkowska, W. F. Symmans, L. Pusztai, P. M. Ravdin, and G. N. Hortobagyi The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine Oncologist, April 1, 2009; 14(4): 320 - 368. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Fonseca, R. Soiffer, V. Ho, M. Vanneman, M. Jinushi, J. Ritz, D. Neuberg, R. Stone, D. DeAngelo, and G. Dranoff Protein disulfide isomerases are antibody targets during immune-mediated tumor destruction Blood, February 19, 2009; 113(8): 1681 - 1688. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Banerji Heat Shock Protein 90 as a Drug Target: Some Like It Hot Clin. Cancer Res., January 1, 2009; 15(1): 9 - 14. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Guo, P. Reigan, D. Siegel, and D. Ross Enzymatic Reduction and Glutathione Conjugation of Benzoquinone Ansamycin Heat Shock Protein 90 Inhibitors: Relevance for Toxicity and Mechanism of Action Drug Metab. Dispos., October 1, 2008; 36(10): 2050 - 2057. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. K. McCollum, C. J. TenEyck, B. Stensgard, B. W. Morlan, K. V. Ballman, R. B. Jenkins, D. O. Toft, and C. Erlichman P-Glycoprotein-Mediated Resistance to Hsp90-Directed Therapy Is Eclipsed by the Heat Shock Response Cancer Res., September 15, 2008; 68(18): 7419 - 7427. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. R. Almon, E. Yang, W. Lai, I. P. Androulakis, D. C. DuBois, and W. J. Jusko Circadian Variations in Rat Liver Gene Expression: Relationships to Drug Actions J. Pharmacol. Exp. Ther., September 1, 2008; 326(3): 700 - 716. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Alaamery and C. S. Hoffman Schizosaccharomyces pombe Hsp90/Git10 Is Required for Glucose/cAMP Signaling Genetics, April 1, 2008; 178(4): 1927 - 1936. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Chatterjee, C. Snead, G. Yetik-Anacak, G. Antonova, J. Zeng, and J. D. Catravas Heat shock protein 90 inhibitors attenuate LPS-induced endothelial hyperpermeability Am J Physiol Lung Cell Mol Physiol, April 1, 2008; 294(4): L755 - L763. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Banerji, A. Affolter, I. Judson, R. Marais, and P. Workman BRAF and NRAS mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors Mol. Cancer Ther., April 1, 2008; 7(4): 737 - 739. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. McCarthy, E. Pick, Y. Kluger, B. Gould-Rothberg, R. Lazova, R. L. Camp, D. L. Rimm, and H. M. Kluger HSP90 as a marker of progression in melanoma Ann. Onc., March 1, 2008; 19(3): 590 - 594. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Consensus Statement Endocr. Relat. Cancer, December 1, 2006; 13(Supplement_1): S1 - S2. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
